DE3682091D1 - Trichostatine a und c als antikrebsmittel. - Google Patents

Trichostatine a und c als antikrebsmittel.

Info

Publication number
DE3682091D1
DE3682091D1 DE8686101047T DE3682091T DE3682091D1 DE 3682091 D1 DE3682091 D1 DE 3682091D1 DE 8686101047 T DE8686101047 T DE 8686101047T DE 3682091 T DE3682091 T DE 3682091T DE 3682091 D1 DE3682091 D1 DE 3682091D1
Authority
DE
Germany
Prior art keywords
trichostatine
drink agent
drink
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8686101047T
Other languages
German (de)
English (en)
Inventor
Teruhiko Beppu
Yasushi Iwamoto
Minoru Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE3682091D1 publication Critical patent/DE3682091D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE8686101047T 1985-01-30 1986-01-27 Trichostatine a und c als antikrebsmittel. Expired - Lifetime DE3682091D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60016085A JPS61176523A (ja) 1985-01-30 1985-01-30 制癌剤

Publications (1)

Publication Number Publication Date
DE3682091D1 true DE3682091D1 (de) 1991-11-28

Family

ID=11906699

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686101047T Expired - Lifetime DE3682091D1 (de) 1985-01-30 1986-01-27 Trichostatine a und c als antikrebsmittel.

Country Status (4)

Country Link
US (1) US4690918A (enExample)
EP (1) EP0196415B1 (enExample)
JP (1) JPS61176523A (enExample)
DE (1) DE3682091D1 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0775593A (ja) * 1993-09-08 1995-03-20 Suntory Ltd 蛋白質の製造方法
EP0827946A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Inhibitors for the differentiation of cells, in particular hepatic stellate cells
WO1998029108A2 (en) * 1996-12-30 1998-07-09 The Johns Hopkins University School Of Medicine Compositions and methods for restoring a normal pattern of imprinting to cells
EP1332756A3 (en) * 1996-12-30 2003-12-10 The Johns Hopkins University School Of Medicine Compositions and methods for restoring a normal pattern of imprinting to cells
US6387673B1 (en) * 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6518012B1 (en) 1999-04-02 2003-02-11 Health Research, Inc. Method for regulating the expression of MHC antigens and CD40 by inhibitors of histone deacetylation
US6544957B2 (en) 2000-01-04 2003-04-08 The Johns Hopkins University Methods and reagents for facilitating transcription
WO2002055017A2 (en) * 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) * 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
ATE305297T1 (de) * 2001-04-10 2005-10-15 Deutsches Krebsforsch Verwendung von histonedeacetylasehemmern zur behandlung von papillomaviren assoziierte krankheiten
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
AU2002315166A1 (en) * 2001-06-15 2003-01-02 The Trustees Of Columbia University In The City Of New York Sir2alpha-based therapeutic and prophylactic methods
WO2003032921A2 (en) * 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US20030147813A1 (en) * 2002-02-07 2003-08-07 John Lyons Method for treating chronic myelogenous leukemia
CA2476434A1 (en) * 2002-02-15 2003-08-28 Sloan-Kettering Institute For Cancer Research Method of treating trx mediated diseases
JP2005519078A (ja) * 2002-02-27 2005-06-30 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション 急性骨髄性白血病の治療方法
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
RU2394022C2 (ru) * 2002-03-04 2010-07-10 МЕРК ЭйчДиЭйСи Рисерч, ЛЛС Способы индукции конечной дифференцировки
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
CA2503150A1 (en) * 2002-10-31 2004-05-21 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
ATE468113T1 (de) 2003-06-27 2010-06-15 Astellas Pharma Inc Therapeutisches mittel für ein weichteilsarkom
US20050037992A1 (en) * 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
PL379887A1 (pl) * 2003-08-26 2006-11-27 Merck Hdac Research, Llc Sposób leczenia raka inhibitorami HDAC
US20050059682A1 (en) * 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
WO2006007377A2 (en) * 2004-06-16 2006-01-19 The General Hospital Corporation Methods of screening for bridge-1-mediated disorders, including type ii diabetes
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060063735A1 (en) * 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
US20060128654A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
US7250416B2 (en) * 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
TWI365068B (en) 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
CA2619568A1 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070117776A1 (en) * 2005-11-04 2007-05-24 John Lyons Low Dose Therapy Of DNA Methylation Inhibitors
WO2007056232A2 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and bortezomib for treating cancer
CN101300015A (zh) * 2005-11-04 2008-11-05 默克公司 使用n-辛二酰苯胺异羟肟酸和厄洛替尼治疗癌症的方法
US20070105792A1 (en) * 2005-11-04 2007-05-10 Dimartino Jorge F Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases
JP2007262058A (ja) * 2006-03-03 2007-10-11 Tokyo Univ Of Science 糸状菌の分化抑制剤
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
WO2008042795A2 (en) * 2006-09-29 2008-04-10 The Board Of Trustees Of The University Of Illinois Histone acetyle transferase activators and histone deacetylase inhibitors in the treatment of alcoholism
EP2086323A4 (en) * 2006-11-03 2010-01-06 Univ Maryland METHOD OF USE OF SAHA AND BORTEZOMIB FOR THE TREATMENT OF MULTIPLE MYELOMA
JP5693850B2 (ja) * 2007-02-06 2015-04-01 リクスト・バイオテクノロジー，インコーポレイテッド オキサビシクロヘプタンおよびオキサビシクロヘプテン、それらの製造および使用
US8043804B2 (en) * 2007-05-23 2011-10-25 The Trustees Of Columbia University In The City Of New York DBC1, a novel native inhibitor of anti-aging protein SIRT1
AU2008284364A1 (en) * 2007-08-03 2009-02-12 Lixte Biotechnology, Inc. Use of phosphatases to treat neuroblastomas and medulloblastomas
EP2200439B1 (en) * 2007-10-01 2017-03-22 Lixte Biotechnology, Inc. Hdac inhibitors
US8227473B2 (en) * 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
AU2009277179A1 (en) * 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
US8058268B2 (en) * 2008-08-01 2011-11-15 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
LT2750768T (lt) 2011-08-30 2019-02-11 Astex Pharmaceuticals, Inc. Decitabino darinio kompozicijos
CN105209036B (zh) 2013-04-09 2018-10-26 莱克斯特生物技术公司 氧杂双环庚烷和氧杂双环庚烯的配制品
EA037638B1 (ru) * 2013-08-22 2021-04-23 Ванда Фармасьютикалз Инк. Лечение множественной миеломы
EA037667B1 (ru) * 2013-08-22 2021-04-28 Ванда Фармасьютикалз Инк. Лечение рака
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
CN108024535A (zh) 2015-07-02 2018-05-11 大塚制药株式会社 冻干药物组合物
US20190119642A1 (en) 2016-03-15 2019-04-25 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
CA3046515A1 (en) 2016-12-08 2018-06-14 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
RU2020108580A (ru) 2017-08-03 2021-09-03 Оцука Фармасьютикал Ко., Лтд. Лекарственное соединение и способы его очистки

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218478A (en) * 1979-01-05 1980-08-19 Ruiko Oiwa Trichostatin as an antiprotozoal agent
JPS60149520A (ja) * 1984-01-13 1985-08-07 Ajinomoto Co Inc 抗腫瘍剤

Also Published As

Publication number Publication date
JPH0466453B2 (enExample) 1992-10-23
EP0196415A3 (en) 1988-09-07
EP0196415B1 (en) 1991-10-23
US4690918A (en) 1987-09-01
JPS61176523A (ja) 1986-08-08
EP0196415A2 (en) 1986-10-08

Similar Documents

Publication Publication Date Title
DE3682091D1 (de) Trichostatine a und c als antikrebsmittel.
NO863185D0 (no) Benmorfogeniske midler.
DE3684108D1 (de) Zementformende mittel.
NO863646D0 (no) Antivirusmiddel.
FI881455L (fi) Respirator.
IT1215651B (it) Agenti cardiotonici antitrombogenici immidazochinolinici.
FI860096L (fi) Haorfaergmedels-preparat.
DE3687461D1 (de) Entwicklungsgeraet.
DE3673718D1 (de) Hydroxy- und alkoxypyrimidine.
DE3650246D1 (de) Entwicklungsverfahren und Gerät.
DE3679764D1 (de) Zaepfchen und grundlage dafuer.
DE3671533D1 (de) Immunotestverfahren und reagenz dafuer.
FI851312L (fi) Fartygs bottenkonstruktion.
DE3678618D1 (de) Entwicklungsvorrichtung.
DE3580479D1 (de) Auftragsvorrichtung.
DE3685945D1 (de) Analysiergeraet.
FI860165A0 (fi) Sidovaegg i en metallurgisk smaeltugn.
DE3682908D1 (de) Fungizides mittel.
DE3675418D1 (de) Entwicklungsvorrichtung.
DE3878774D1 (de) Paraherquamid und dihydroparaherquamid als antiparasitaere mittel.
FI861193L (fi) Stabilt gammainterferonpreparat.
DE3680771D1 (de) Isoxazolopyridophenoxazin- und isothiazolopyridophenoxazinderivate.
DE3680692D1 (de) Kreisel.
DE3679122D1 (de) Trageinheit.
DE3680775D1 (de) Isoxazolopyridobenzoxazin- und isothiazolopyridobenzoxazinderivate.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee